Department of Neurology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, P.R. China.
Int J Neurosci. 2021 Jan;131(1):25-30. doi: 10.1080/00207454.2020.1732972. Epub 2020 Mar 3.
To study the influence of butyphthalide combined with urinary kallikrein in acute cerebral infarction (ACI) treatment on neuro-cytokines and indicators of vascular endothelial function, observe the curative effect and adverse effects, and discuss its safety and feasibility. 110 ACI patients were chosen as the objects, and classified into observation group (55 cases) and control group (55 cases) according to the method of random number table. Butyphthalide injection combined with urinary kallikrein was adopted for the observation group based on conventional treatment, while cinepazide maleate injection combined with alprostadil injection was applied for the control group based on conventional treatment. The following indicators of both groups were compared before and after treatment: neurotrophic factor (NTF), nerve growth factor (NGF), neuron specific enolase (NSE); content of CXC chemotactic factor ligand 16 (CXCL16), soluble CD ligand (CD40L), Fibulin-5 and high mobility group box B1 (HMGB1); the content of indicators of vascular endothelial function including plasma endothelin -1 (ET-1) and no therapeutic effects and adverse effects were recorded. NSE of both groups after treatment decreased obviously, and the content of NTF and NGF increased obviously. NSE content of observation group was lower than that of control group. NTF content and NGF content of observation group were higher than those of control group. The differences had statistical significance ( < 0.05). The levels of CXCL16, CD40L, Fibulin-5 and HMGB1 declined obviously, compared with pre-treatment, and the levels of observation groups were significantly lower than those of control grip. The differences had statistical significance ( < 0.05). ET-1 level rose significantly after treatment, and NO level declined obviously after treatment. ET-1 level of observation group was significantly higher than that of control group, and NO level of observation group was significantly lower than that of control group. The difference had statistical significance ( < 0.05). Clinical effect of observation group was significantly higher than that of control group. The difference had statistical significance ( < 0.05). The comparison difference of both groups in the occurrence rate of adverse effects had no statistical significance ( > 0.05). The application of butyphthalide combined with urinary kallikrein in ACI treatment can effectively inhibit secretion and release of neuro-cytokines, and improve patients' vascular endothelial function, with significant treatment effect and high safety. Therefore, it deserves to be promoted clinically.
为了研究丁苯酞联合激肽原在急性脑梗死（ACI）治疗中对神经细胞因子和血管内皮功能指标的影响，观察疗效和不良反应，并探讨其安全性和可行性，选择 110 例 ACI 患者，按照随机数字表法分为观察组（55 例）和对照组（55 例）。观察组在常规治疗的基础上采用丁苯酞注射液联合激肽原治疗，对照组在常规治疗的基础上采用马来酸桂哌齐特注射液联合前列地尔注射液治疗。比较两组患者治疗前后的神经生长因子（NGF）、神经节苷脂（NTF）、神经元特异性烯醇化酶（NSE）；趋化因子配体 16（CXCL16）、可溶性 CD40 配体（CD40L）、纤连蛋白 5（Fibulin-5）和高迁移率族蛋白 B1（HMGB1）含量；血管内皮功能指标包括血浆内皮素-1（ET-1）的含量等，记录两组患者的治疗效果及不良反应发生情况。两组患者治疗后 NSE 明显下降，NTF、NGF 含量明显升高，观察组 NSE 含量低于对照组，NTF 含量和 NGF 含量高于对照组，差异均有统计学意义（ < 0.05）。两组患者治疗后 CXCL16、CD40L、Fibulin-5、HMGB1 水平明显下降，观察组明显低于对照组，差异均有统计学意义（ < 0.05）。两组患者治疗后 ET-1 水平明显升高，NO 水平明显下降，观察组 ET-1 水平明显高于对照组，NO 水平明显低于对照组，差异均有统计学意义（ < 0.05）。观察组患者的临床疗效明显高于对照组，差异有统计学意义（ < 0.05）。两组患者不良反应发生率比较，差异无统计学意义（ > 0.05）。结论：在 ACI 治疗中应用丁苯酞联合激肽原可以有效抑制神经细胞因子的分泌和释放，改善患者的血管内皮功能，治疗效果显著，安全性高，值得临床推广。
